Healthcare | February 24, 2022
Experts point out key issues for vision loss at ASSOCHAM meet
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
DR devices today should do more than just provide crystal clear imaging and assist during diagnosis. Hence, the ImageView Software used in DRX Compass offers upgraded cybersecurity
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
It will open new frontier for south-to-south collaboration and innovation transfer
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
